Hanna Radomska, PhD.
Research Scientist
Radomska.1@osu.edu
Dr. Hanna Radomska is a Research Scientist within the Comprehensive Cancer Center at The Ohio State University. She has an extensive experience in the field of hematology/oncology with the vast understanding of the role of transcription factors and signaling pathways in oncological diseases. She has years of experience in molecular biology, including CRISPR technology.
Currently, she is involved in multiple projects focused on cancer cachexia, estrogen receptor (ER) signaling, and the role of androgen receptor (AR) in HCC, with the aim of development of novel and effective therapeutic interventions. Her role on the proposed project involves genetic modification of model HCC cell lines using CRISPR methodology. She is creating AR-null and AR-overexpressing HCC cell lines, which will be used for in vivo studies to evaluate the roles of AR full length (AR-FL) and splice variants (AR-SV) in HCC tumorigenicity and testing responsiveness of those HCC tumors to AR-targeted therapies.
Her education includes:
Gdańsk University, Gdańsk, Poland; M.Sc.; 10/1980 Biology
Columbia University, New York, N.Y.; M.Phil.; 05/1992 Molecular Biology
Columbia University, New York, N.Y.; Ph.D.; 10/1994 Molecular Biology
Her fellowships and awards include:
2002-2004: K01 DK, NIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Research Scientist Development Award – Research & Training
2000-2001: Harvard Medical School, Scholar in Medicine Award
1997-1999: F32 DK, NIH, National Research Service Award